RU2014103572A - PHARMACEUTICAL COMPOSITIONS OF 3- (3,4,5-TRIMETOXYBENZOYLOXYIMINO) -8-METHYL-8-AZABicyclo- [3,2,1] OCTAN WITH LONG-LAST RELEASE - Google Patents
PHARMACEUTICAL COMPOSITIONS OF 3- (3,4,5-TRIMETOXYBENZOYLOXYIMINO) -8-METHYL-8-AZABicyclo- [3,2,1] OCTAN WITH LONG-LAST RELEASE Download PDFInfo
- Publication number
- RU2014103572A RU2014103572A RU2014103572/15A RU2014103572A RU2014103572A RU 2014103572 A RU2014103572 A RU 2014103572A RU 2014103572/15 A RU2014103572/15 A RU 2014103572/15A RU 2014103572 A RU2014103572 A RU 2014103572A RU 2014103572 A RU2014103572 A RU 2014103572A
- Authority
- RU
- Russia
- Prior art keywords
- cellulose
- methocel
- pharmaceutical composition
- composition according
- premium
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
1. Фармацевтические композиции, содержащие гидрохлорид 3-(3,4,5-триметоксибензоилоксиимино)-8-метил-8-азабицикло[3,2,1]октана в эффективном количестве, с пролонгирующим полимером и фармацевтически приемлемыми вспомогательными веществами, пригодными для использования в фармацевтических композициях с пролонгированным высвобождением при следующем соотношении компонентов в твердой лекарственной форме (мас. %):Гидрохлорид 3-(3,4,5-триметоксибензоилоксиимино)-8-метил-8-азабициклогде в качестве пролонгирующего полимера используется по меньшей мере один, выбранный из группы, включающей производные целлюлозы (этилцеллюлоза, гидроксипропилцеллюлоза, гидроксипропилметилцеллюлоза, гидроксиэтилцеллюлоза), выпускаемые в промышленности под наименованиями: Methocel® К4М Premium CR, Methocel® K100M Premium CR, Methocel A15 Premium LV, Methocel E6 Premium LV, Methocel K100 Premium LV (DOW Chemical, США); Walocel HM 15PA, Walocel HM 100000 PA (Wolff Cellulosics, концерн "Bayer AG"), Bonucel, Retardcel (Biogrund, Германия); и акриловой кислоты (редкосшитые акриловые полимеры, метакриловая кислота, этилакрилат, триметиламмониоэтилметакрилат и их сополимеры), выпускаемые промышленностью под наименованиями: Eudragit RS РО (Evonik, Германия), Carbopol 71G (Noveon, США); полиэтиленгликоли (ПЭГ), поливинилацетатов/поливинилпирролидонов (Kollidon SR);в качестве вспомогательных веществ, обеспечивающей достаточную массу твердой лекарственной форме (наполнителя), может содержать, по меньшеймере, одно вещество, выбранное из группы: микрокристаллическая целлюлоза, лактоза, кальция фосфат, кальция дигидрофосфат, кальция гидрофосфат дигидрат, кальция сульфат дигидрат, кальция карбонат основной, производные поливинилпирролидона; вспомогательные вещества с повышенн1. Pharmaceutical compositions containing 3- (3,4,5-trimethoxybenzoyloxyimino) -8-methyl-8-azabicyclo [3.2.1] octane hydrochloride in an effective amount, with a prolonging polymer and pharmaceutically acceptable excipients suitable for use in pharmaceutical compositions with sustained release in the following ratio of components in solid dosage form (wt.%): 3- (3,4,5-trimethoxybenzoyloxyimino) -8-methyl-8-azabicyclohydrochloride, as a prolonged polymer, at least one selected from the group consisting of cellulose derivatives (ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose) commercially available under the names: Methocel® K4M Premium CR, Methocel® K100M Premium CR, Methocel A15 Premium LV, Methocel E6 Premium LV, Methocel K6 Premium LV, Methocel LV (DOW Chemical, USA); Walocel HM 15PA, Walocel HM 100000 PA (Wolff Cellulosics, Bayer AG), Bonucel, Retardcel (Biogrund, Germany); and acrylic acid (cross-linked acrylic polymers, methacrylic acid, ethyl acrylate, trimethylammonioethyl methacrylate and their copolymers), manufactured by the industry under the names: Eudragit RS PO (Evonik, Germany), Carbopol 71G (Noveon, USA); polyethylene glycols (PEG), polyvinyl acetates / polyvinylpyrrolidones (Kollidon SR); as auxiliary substances, providing an adequate mass of solid dosage form (excipient), may contain at least one substance selected from the group: microcrystalline cellulose, lactose, calcium phosphate, calcium dihydrogen phosphate, calcium hydrogen phosphate dihydrate, calcium sulfate dihydrate, basic calcium carbonate, derivatives of polyvinylpyrrolidone; excipients with increased
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014103572/15A RU2014103572A (en) | 2014-02-04 | 2014-02-04 | PHARMACEUTICAL COMPOSITIONS OF 3- (3,4,5-TRIMETOXYBENZOYLOXYIMINO) -8-METHYL-8-AZABicyclo- [3,2,1] OCTAN WITH LONG-LAST RELEASE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014103572/15A RU2014103572A (en) | 2014-02-04 | 2014-02-04 | PHARMACEUTICAL COMPOSITIONS OF 3- (3,4,5-TRIMETOXYBENZOYLOXYIMINO) -8-METHYL-8-AZABicyclo- [3,2,1] OCTAN WITH LONG-LAST RELEASE |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014103572A true RU2014103572A (en) | 2015-10-10 |
Family
ID=54289196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014103572/15A RU2014103572A (en) | 2014-02-04 | 2014-02-04 | PHARMACEUTICAL COMPOSITIONS OF 3- (3,4,5-TRIMETOXYBENZOYLOXYIMINO) -8-METHYL-8-AZABicyclo- [3,2,1] OCTAN WITH LONG-LAST RELEASE |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2014103572A (en) |
-
2014
- 2014-02-04 RU RU2014103572/15A patent/RU2014103572A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2568391C (en) | Coated tablet formulation and method | |
CA2552569A1 (en) | Direct compression formulation and process | |
JP2009545560A5 (en) | ||
JP2013521333A (en) | Delayed sustained drug delivery | |
UA116784C2 (en) | A solid oral pharmaceutical formulation containing ticagrelor | |
RU2015107517A (en) | PHARMACEUTICAL COMPOSITIONS OF MEMANTINE | |
WO2007025182A3 (en) | Drug compositions containing controlled release hypromellose matrices | |
WO2011045775A4 (en) | A delayed release pharmaceutical composition of mesalamine | |
EP2915527A1 (en) | Pharmaceutical formulations of vildagliptin | |
RU2014103572A (en) | PHARMACEUTICAL COMPOSITIONS OF 3- (3,4,5-TRIMETOXYBENZOYLOXYIMINO) -8-METHYL-8-AZABicyclo- [3,2,1] OCTAN WITH LONG-LAST RELEASE | |
CA3085455C (en) | A solid oral dosage form comprising linagliptin | |
JP5461084B2 (en) | Pharmaceutical composition for oral administration of paroxetine hydrochloride hydrate with suppressed decay delay | |
WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
CA2797458A1 (en) | Tablet formulation of ezatiostat | |
RU2013150254A (en) | Oral Solid Product of the Combined Anti-Tuberculosis Drug and Method for its Preparation | |
KR101460783B1 (en) | Pharmaceutical composition of candesartan cilexetil with improved stability and method for preparing thereof | |
CN102008456A (en) | Novel skeleton sustained release tablet containing metoprolol succinate | |
RU2009139656A (en) | PROLONGED PHARMACEUTICAL COMPOSITION, MEDICINAL FORM AND METHOD OF ITS PRODUCTION (OPTIONS) | |
RU2007133793A (en) | COMPOSITIONS WITH CONTROLLED ALFUZOSINE RELEASE | |
RU2014105636A (en) | PHARMACEUTICAL COMPOSITIONS WITH PROLONGED RELEASE FOR THE TREATMENT OF CEREBROVASCULAR DISORDERS | |
RU2014145845A (en) | SLOW-DELIVER TABLET CONTAINING LEVODROPROPIZIN AND METHOD FOR ITS MANUFACTURE | |
CN101756977A (en) | Slow-release preparation of azelnidipine and preparation method thereof | |
US20120058185A1 (en) | Stable pharmaceutical compositions of olanzapine and process for their preparation | |
RU2377989C2 (en) | Trimetazidine preparation as matrix tablet of prolonged action and method for making thereof | |
RU2012135595A (en) | PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE WITH ANTIPSYCHOTIC ACTIVITY AND METHODS FOR PRODUCING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HE9A | Changing address for correspondence with an applicant | ||
FA91 | Application withdrawn (on applicant's request) |
Effective date: 20170203 |